Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Sam Schulman(Hamilton General Hospital), Clive Kearon(McMaster University), Samuel Z. Goldhaber(Brigham and Women's Hospital), Sebastian Schellong(Krankenhaus Dresden-Friedrichstadt), Anita Vedel Christiansen(Boehringer Ingelheim (Germany)), Jeffrey Friedman(Boehringer Ingelheim (United States)), Florence Le Maulf(Boehringer Ingelheim (Germany)), Ajay K. Kakkar(Queen Mary University of London), Patrick Mismetti, Henry Eriksson(Sahlgrenska University Hospital), Nuala Peter(Thrombosis Research Institute)
Cited by 930
Related Papers
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients
|Journal of Thrombosis and Haemostasis|2005|4.9k
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
|Journal of Thrombosis and Haemostasis|2009|3.8k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Prevention of VTE in Nonsurgical Patients
|CHEST Journal|2012|2.7k
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
|New England Journal of Medicine|2009|2.6k